Leave your contact details and we will contact you
The cost of services is determined by their scope and content and is calculated upon request via email at info@rncph.ru
Home
Analytical databases
We produce accurate analytical tools
RNC Pharma provides partners with a wide range of syndicated projects on
the analyzed markets
Contact us
Contact us
About project
We provide 24/7 remote access from any part of the world through an intuitive and clear online interface
User access allows to construct reports of the required structure and upload them to users' devices in a table format (xlsx or csv). Clients have the access to a flexible system of user settings, including advanced search and filtering features, customizing and saving your own templates. RNC Pharma specialists provide the training for new users and operational support to customers when it is needed
Retail sales audit
This block of projects allows us to analyze operational processes that take place in the retail segment of the Russian pharmaceutical and related markets in order to conduct competitive analysis, monitor the effectiveness of marketing activities, evaluate the distribution levels of specific products, commodity neighborhood, size of the average check, etc.
Production of pharmaceuticals in Russia
The project allows estimating the actual output of specific products, including the launch of new drugs that have not entered the distribution system yet. It tracks import substitution trends, estimates the amount of actual demand for
active pharmaceutical ingredients, auxiliary substances and packaging materials
21.01.2026
On the Russian retail pharmaceutical market, 18.5 million packs of gastroprokinetic and antiemetic medicines were sold over the first eleven months of 2025, which is 5.1% higher than in the same period of 2024.
20.01.2026
The Russian retail market for fillers and biorevitalizers in January–November 2025 demonstrated the highest growth in value terms over the past three years. Compared with the same period of 2024, sales value increased by 33.8% in ruble terms and reached RUB 34.1 billion.
15.01.2026
During the period from January to November 2025, the Russian retail market for immunomodulators, excluding interferons and colony-stimulating factors, amounted to RUB 17.9 billion at retail prices.
14.01.2026
Based on the results for January–November 2025, Russian consumers purchased 21 million packs of drugs from the hepatoprotectors and lipotropic agents group.
13.01.2026
Based on the results for January–November 2025, a total of 9.98 million medical thermometers of all types were sold on the Russian retail market, including marketplaces and the FMCG channel, with total sales amounting to RUB 3.18 billion at retail prices, including VAT.
12.01.2026
As a result of January–November 2025, the Russian retail market for enterosorbent medicines (group A07B under the EphMRA classification) exceeded RUB 13.1 billion at retail prices, including VAT. Total consumer spending in the category grew by 7.9% compared with the same period of 2024.
23.12.2025
Retail sales of botulinum toxin products in Russia including specialized retail, pharmacies, and the clinical segment reached RUB 13.1 billion in January–October 2025 at retail prices, including VAT.
22.12.2025
In the first ten months of 2025, retail sales of laxatives (EphMRA group A06A) in Russia, including the online channel, reached 43.4 million packs with a total market value of RUB 15.0 billion at retail prices.